Lansoprazol Mabo

Lansoprazole, the active ingredient in Lansoprazol Mabo, is a proton pump inhibitor presented as an oral dosage form for oral use. It reduces gastric acid secretion and is indicated for conditions such as gastro‑esophageal reflux disease, erosive esophagitis, peptic ulcer disease, and for use in Helicobacter pylori eradication regimens. GNH USA supplies Lansoprazol Mabo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lansoprazol Mabo, a proton pump inhibitor, is employed to manage acid‑related gastrointestinal disorders.

- Gastro‑esophageal reflux disease (GERD): reduces reflux symptoms and promotes healing of esophageal irritation. - Erosive esophagitis: facilitates mucosal repair by decreasing acid exposure. - Peptic ulcer disease: supports ulcer healing and prevents recurrence. - Helicobacter pylori eradication (in combination therapy): enhances eradication rates by suppressing gastric acidity. - Prevention of NSAID‑induced gastric ulcers: lowers risk of ulcer formation in patients using non‑steroidal anti‑inflammatory drugs.

Lansoprazol Mabo may cause a range of adverse reactions.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: loose stools occurring intermittently. - Nausea: feeling of stomach upset. - Abdominal pain: discomfort or cramping in the stomach area.

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis): difficulty breathing, swelling, rash. - Clostridium difficile infection: persistent diarrhea with possible colitis. - Liver enzyme elevation: signs of hepatic dysfunction. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions.

Before prescribing Lansoprazol Mabo, consider the following safety measures.

- Renal function assessment: adjust use in patients with severe kidney disease. - Hepatic impairment: use with caution in moderate to severe liver dysfunction. - Discontinuation: avoid abrupt cessation to prevent rebound acid hypersecretion. - Infection monitoring: watch for signs of gastrointestinal infections, especially C. difficile. - Drug interaction review: evaluate concomitant medications that may alter acid levels. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lansoprazol Mabo can affect the absorption and metabolism of several drugs.

Major Interactions (Avoid): - Atazanavir: reduced antiviral efficacy due to decreased gastric acidity. - Ketoconazole: impaired antifungal absorption. - Nelfinavir: decreased plasma concentrations. - Rilpivirine: reduced bioavailability.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in anticoagulant effect. - Phenytoin: possible reduction in anticonvulsant levels. - Digoxin: altered serum concentrations. - Methotrexate: increased risk of toxicity. - Clopidogrel: diminished antiplatelet activity.